about
Combating Tuberculosis Infection: A Forbidding ChallengeWhole-genome sequencing targets drug-resistant bacterial infectionsBiochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug targetVirtual Screening of Peptide and Peptidomimetic Fragments Targeted to Inhibit Bacterial Dithiol Oxidase DsbABibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015)Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme.In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.Anti-Mycobacterial Evaluation of 7-Chloro-4-Aminoquinolines and Hologram Quantitative Structure-Activity Relationship (HQSAR) Modeling of Amino-Imino Tautomers.In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosisSyntheses of new tuberculosis inhibitors promoted by microwave irradiationA High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.Structure and mechanism of the ATP synthase membrane motor inferred from quantitative integrative modeling.Future target-based drug discovery for tuberculosis?The anti-tuberculosis agents under development and the challenges ahead.Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation.Drug Resistance Mechanisms in Mycobacterium tuberculosis.The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in ChinaPredicted Structures of the Proton-Bound Membrane-Embedded Rotor Rings of the Saccharomyces cerevisiae and Escherichia coli ATP Synthases.In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.Mycobacterium tuberculosis Proteome Response to Antituberculosis Compounds Reveals Metabolic "Escape" Pathways That Prolong Bacterial Survival.Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent
P2860
Q26750683-E2AF372F-24DE-4AA0-B68B-9FC70F6F2E7AQ26799059-E0CAA973-25CD-4E49-A458-77282C44C617Q28545065-4616574C-C0D2-423D-B9B3-FB91C2C328E2Q28546904-C1C681D9-82CD-444C-A694-E16DD9184FC8Q28555235-EB733B05-0A97-46BA-9E8E-AFC012EF0CD2Q33594281-7F93AA9B-7BCA-474F-87BE-E0A0C52731E9Q33798527-63955CD2-6C03-46A9-A501-A0B4DD14E210Q33851536-837DB15F-4964-44D6-B648-5F52DE9D9D66Q34922070-7D0312F7-4B53-4B13-B077-A84A6F700068Q35130531-DB81BD4A-CA0F-487A-9992-2AB88A3A82DFQ36329737-E5189CD5-65D3-47C2-9568-FDD1F0EE9D5FQ36681757-CFD901C5-2684-47E7-B34B-399160E7C63EQ37457022-D8F98BB8-7744-4FFB-9A9A-08102BAF079CQ38280137-0174CA07-88ED-4F21-8CA0-004DE24EFA52Q38617197-E3C98949-3293-427D-9551-075E0B04E384Q38718136-5C58174B-53A9-4FC0-9EEE-E164B0FBA4AFQ38792870-71B9ABA7-C8FE-4FF7-819A-67F295EB91F0Q38806183-5C9D1E88-C754-4CFA-9E19-C21F3D54942EQ38938704-7AC36BD2-7FEE-4FF8-92FD-1B1BD1E0BC0EQ39313354-FD9B2B7A-F3B9-44AC-968B-B2851BCBDE21Q40117387-E545C295-D3B2-4C4A-95D1-31655FF31FC4Q40248080-BD7F3EE5-778A-40A3-95E8-3BDB672EEE55Q57191759-D69AC22A-D38E-4CA6-9E7A-A8AC9C686A4B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
TMC207 becomes bedaquiline, a new anti-TB drug.
@en
type
label
TMC207 becomes bedaquiline, a new anti-TB drug.
@en
prefLabel
TMC207 becomes bedaquiline, a new anti-TB drug.
@en
P2860
P356
P1433
P1476
TMC207 becomes bedaquiline, a new anti-TB drug.
@en
P2093
Anandi Martin
Juan Carlos Palomino
P2860
P304
P356
10.2217/FMB.13.85
P577
2013-09-01T00:00:00Z